1 – 29 of 29
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
(
- Contribution to journal › Article
- 2023
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
- 2022
-
Mark
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up
(
- Contribution to journal › Article
-
Mark
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
(
- Contribution to journal › Article
-
Mark
The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Disseminated tumour cells from the bone marrow of early breast cancer patients : Results from an international pooled analysis
(
- Contribution to journal › Article
-
Mark
St Gallen 2019 guidelines understage the axilla in lobular breast cancer : a population-based study
(
- Contribution to journal › Article
- 2020
-
Mark
The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast –long term prognostic significant
(
- Contribution to journal › Article
-
Mark
Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial
(
- Contribution to journal › Article
-
Mark
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
(
- Contribution to journal › Article
-
Mark
Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer
(
- Contribution to journal › Article
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
(
- Contribution to journal › Article
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
(
- Contribution to journal › Article
-
Mark
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
(
- Contribution to journal › Article
- 2018
-
Mark
Stability of oestrogen and progesterone receptor antigenicity in formalin‐fixed paraffin‐embedded breast cancer tissue over time
(
- Contribution to journal › Article
-
Mark
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
(
- Contribution to journal › Article
- 2017
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffinblocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
-
Mark
Tumor tissue protein signatures reflect histological grade of breast cancer
2017) In PLoS ONE(
- Contribution to journal › Article
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
(
- Contribution to conference › Abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article
- 2013
-
Mark
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
(
- Contribution to journal › Article
-
Mark
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
(
- Contribution to journal › Article
-
Mark
Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution.
(
- Contribution to journal › Article
- 2012
-
Mark
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study
(
- Contribution to journal › Article
- 2010
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
High amplified in breast cancer 1 is a significant predictor of improved response to adjuvant tamoxifen in premenopausal women
2008) 31st Annual San Antonio Breast Cancer Symposium(
- Contribution to conference › Abstract